• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨细胞动脉炎患者的视力相关和健康相关生活质量。

Vision-related and health-related quality of life in patients with giant cell arteritis.

机构信息

Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.

Department of Ophthalmology, RCSI School of Medicine, Dublin, Ireland.

出版信息

Eur J Ophthalmol. 2021 Mar;31(2):727-733. doi: 10.1177/1120672120901693. Epub 2020 Jan 20.

DOI:10.1177/1120672120901693
PMID:31957482
Abstract

OBJECTIVE

To establish if there is a difference in health-related quality of life and vision-related quality of life in patients with a confirmed diagnosis of giant cell arteritis compared with those with clinical features suspicious for the disease at initial presentation but in whom giant cell arteritis is ultimately excluded.

METHODS

A cross-sectional study of 116 patients who presented to two tertiary referral hospitals in Ireland with symptoms suspicious for giant cell arteritis was performed between August 2011 and June 2017. The Vision Core Measurement 1 and Short Form-36 questionnaires were used as assessment tools.

RESULTS

The mean (standard deviation) age of all 116 participants was 69.4 (9.3) years of whom 74 (63.8%) were female. In the giant cell arteritis group, 19.7% had permanent loss of vision and 54.7% had non-permanent visual disturbance. Vision Core Measurement 1 score in the giant cell arteritis group correlated with worse eye visual acuity (r = 0.4233, p = 0.0002). The Short Form-36 subscales of role physical (p = 0.0002), role emotional (p = 0.024), and the mental composite score (p = 0.012) were significantly worse in patients with giant cell arteritis. A significant correlation was found between vision-related quality of life scores and all Short Form-36 subscale scores except bodily pain (r = -0.215 to -0.399, p < 0.05 for all), and between social functioning and visual acuity in the better eye (r = -0.242, p = 0.038).

CONCLUSION

Vision-related quality of life is an important subjective concern for both patients presenting with a suspicion of giant cell arteritis and those with a definite diagnosis of giant cell arteritis. Features of giant cell arteritis impact on patients' physical and emotional states and vision influences global quality of life in giant cell arteritis. A long-term multidisciplinary approach is warranted for clinical, physical, and psychological treatment and support.

摘要

目的

确定经临床确诊的巨细胞动脉炎患者与最初表现出巨细胞动脉炎临床特征但最终排除巨细胞动脉炎的患者相比,其健康相关生活质量和视力相关生活质量是否存在差异。

方法

对 2011 年 8 月至 2017 年 6 月间在爱尔兰两家三级转诊医院就诊的 116 例疑似巨细胞动脉炎症状的患者进行了横断面研究。使用视力核心测量 1 和简明 36 健康状况调查简表作为评估工具。

结果

116 名参与者的平均(标准差)年龄为 69.4(9.3)岁,其中 74 名(63.8%)为女性。在巨细胞动脉炎组中,19.7%的患者永久性失明,54.7%的患者存在非永久性视力障碍。巨细胞动脉炎组的视力核心测量 1 评分与较差的视力(r=0.4233,p=0.0002)相关。巨细胞动脉炎患者的简明 36 健康状况调查简表的身体角色(p=0.0002)、情感角色(p=0.024)和精神综合评分(p=0.012)等子量表评分明显较差。视力相关生活质量评分与除躯体疼痛外的所有简明 36 健康状况调查简表子量表评分(r=-0.215 至-0.399,p<0.05)以及社会功能与较好眼视力之间存在显著相关性(r=-0.242,p=0.038)。

结论

视力相关生活质量是疑似巨细胞动脉炎患者和确诊巨细胞动脉炎患者均关注的重要主观问题。巨细胞动脉炎的特征会影响患者的身体和情绪状态,而视力则会影响巨细胞动脉炎患者的整体生活质量。需要采取长期的多学科方法进行临床、身体和心理治疗和支持。

相似文献

1
Vision-related and health-related quality of life in patients with giant cell arteritis.巨细胞动脉炎患者的视力相关和健康相关生活质量。
Eur J Ophthalmol. 2021 Mar;31(2):727-733. doi: 10.1177/1120672120901693. Epub 2020 Jan 20.
2
Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision.巨细胞动脉炎的视力损害。视力的临床特征及预后
Ophthalmology. 1994 Nov;101(11):1779-85. doi: 10.1016/s0161-6420(94)31102-x.
3
Ophthalmic manifestations of giant cell arteritis.巨细胞动脉炎的眼部表现。
Br J Hosp Med (Lond). 2011 Jan;72(1):26-30. doi: 10.12968/hmed.2011.72.1.26.
4
Poor prognosis of visual outcome after visual loss from giant cell arteritis.巨细胞动脉炎导致视力丧失后视力预后较差。
Ophthalmology. 2005 Jun;112(6):1098-103. doi: 10.1016/j.ophtha.2005.01.036.
5
Ophthalmic presentation of giant cell arteritis in African-Americans.非裔美国人巨细胞动脉炎的眼部表现
Eye (Lond). 2017 Jan;31(1):113-118. doi: 10.1038/eye.2016.199. Epub 2016 Sep 16.
6
Visual function and quality of life among patients with giant cell (temporal) arteritis.巨细胞(颞)动脉炎患者的视觉功能与生活质量
J Neuroophthalmol. 2001 Dec;21(4):266-73. doi: 10.1097/00041327-200112000-00008.
7
Occult giant cell arteritis: ocular manifestations.隐匿性巨细胞动脉炎:眼部表现
Am J Ophthalmol. 1998 Apr;125(4):521-6. doi: 10.1016/s0002-9394(99)80193-7.
8
Complete recovery of visual acuity in two patients with giant cell arteritis.两名巨细胞动脉炎患者视力完全恢复。
Swiss Med Wkly. 2007 May 5;137(17-18):265-8. doi: 10.4414/smw.2007.11863.
9
Domains of health-related quality of life important to patients with giant cell arteritis.对巨细胞动脉炎患者而言重要的健康相关生活质量领域。
Arthritis Rheum. 2003 Dec 15;49(6):819-25. doi: 10.1002/art.11464.
10
[Vision-and health-related quality of life in patients with uveitis].[葡萄膜炎患者的视力与健康相关生活质量]
Zhonghua Yan Ke Za Zhi. 2016 Jun 11;52(6):429-36. doi: 10.3760/cma.j.issn.0412-4081.2016.06.007.

引用本文的文献

1
Anxiety and depression in patients with giant cell arteritis.巨细胞动脉炎患者的焦虑和抑郁
Rheumatol Adv Pract. 2024 Jan 30;8(1):rkae013. doi: 10.1093/rap/rkae013. eCollection 2024.
2
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛的靶向治疗建议。
Ann Rheum Dis. 2024 Jan 2;83(1):48-57. doi: 10.1136/ard-2022-223429.
3
Comment on: Benchmarking tocilizumab use for giant cell arteritis.关于“托珠单抗治疗巨细胞动脉炎的基准评估”的评论
Rheumatol Adv Pract. 2022 Aug 23;6(3):rkac069. doi: 10.1093/rap/rkac069. eCollection 2022.
4
Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review.用于抗中性粒细胞胞浆抗体相关性血管炎的结局测量工具的心理计量学特性:系统文献回顾。
Rheumatology (Oxford). 2022 Nov 28;61(12):4603-4618. doi: 10.1093/rheumatology/keac175.
5
Patient Reported Outcomes in Large Vessel Vasculitides.大血管血管炎患者报告的结局。
Curr Rheumatol Rep. 2021 Jan 28;23(2):7. doi: 10.1007/s11926-020-00979-4.